7 research outputs found

    Pattern of differential expression of costimulatory molecules in myeloma cell line MM1.R

    No full text
    T cells constantly recognise and eliminate circulating tumour cells. They require two signals in order to be activated: antigen presentation via TCR, and costimulatory interaction with different surface molecules of the B7 family, which may either enhance or attenuate immune response. In several cancers these molecules are deregulated, thereby promoting immune escape and the settlement or migration of cancer cells. In multiple myeloma, the expression of B7 co-inhibitory molecules and their relationship to disease progression have been identified. The MM1.R cell line is a useful cellular model for studying the progression of this disease, and therefore an analysis of the pattern of expression in this cell line helps to cast light on the immune status of this disease. Using a real-time PCR (quantitative RT-PCR) assay, we found that the main molecules expressed were those with an inhibitory function (B7-H1, B7-H3 and B7-H4), which suggests a high level of immune inhibition by these cells. Resumen: El reconocimiento y eliminaci贸n constante de c茅lulas tumorales circulantes se logra principalmente mediante la acci贸n de los linfocitos T, c茅lulas cuya activaci贸n requiere de dos se帽ales para poder llevarse a cabo: la presentaci贸n del ant铆geno a trav茅s del TCR y una interacci贸n co-estimuladora liderada por distintas mol茅culas de superficie de la familia B7 que pueden potenciar o atenuar la respuesta. En varios tipos de c谩ncer, estas mol茅culas se encuentran desreguladas, favoreciendo el escape inmunol贸gico y el asentamiento y/o migraci贸n de las c茅lulas neopl谩sicas. En mieloma m煤ltiple se ha identificado la expresi贸n de mol茅culas B7 co-inhibitorias y su relaci贸n con la progresi贸n de la enfermedad. La l铆nea celular MM.1R es un modelo celular 煤til para estudiar la progresi贸n de esta enfermedad, por lo que el an谩lisis del patr贸n de expresi贸n en esta l铆nea celular contribuye a entender el estado inmunol贸gico en la enfermedad. Mediante un ensayo de RT-PCR en tiempo real (qRT-PCR) encontramos que las mol茅culas mayormente expresadas fueron aquellas con funci贸n inhibitoria (B7H1, B7H3 y B7H4), lo cual indica una alta inhibici贸n inmunol贸gica por parte de estas c茅lulas. Keywords: Multiple myeloma, MM1.R, Costimulatory molecules, B7, PCR, Palabras clave: Mieloma m煤ltiple, MM1.R, Coestimuladoras, B7, PC

    Expression of cancer testis antigens in patients with Hodgkin's lymphoma and their clinical correlation

    No full text
    Objective: To determine the frequency of expression of cancer testis antigens and their clinical correlation in patients with Hodgkin lymphoma. Methodology of the study: In this analytical, experimental and ambispective study, the MAGE A-3 and NY-ESO-1 antigen expression was correlated with clinical prognostic variables such as clinical stage, response to treatment, and relapse, in a total of 70 patients diagnosed with Hodgkin's lymphoma at the Hodgkin's Lymphoma Clinic of the General Hospital of Mexico 鈥淒r. Eduardo Liceaga鈥, from December 2000 to December 2015. Twenty-four patients were evaluated using RT-PCR, following extraction of RNA, to detect MAGE-A3 and NY-ESO1 expression. Cellular RNA was extracted from frozen tissue and controls using trizol (Life Technologies, Paisley, UK). 1聽渭g of RNA was used for cDNA synthesis by M-MLV reverse transcriptase (Life technologies, Paisley, UK). Results: We studied 24 patients with a median age of 28 years, a minimum age of 16 years and a maximum age of 48 years, mostly male. 50% of patients presented complete response to the first line of treatment and 27% of patients presented relapse, 37.5% in relation to the expression of MAGE-A3. Expression of the NY-ESO-1 gene was not found in the study group. Twelve percent of patients died during the study, 8.33% of whom were also positive for MAGE-A3 (p聽=聽0.264.95% CI). No significant correlation was found between MAGE-A3 expression and major clinical prognostic variables. Conclusion: Although the expression of MAGE-A3 in the study group was 37.5% (higher than reported in international studies), we found no correlation with the main clinical prognostics variables. Considering that the expression of MAGE-A3 in the cases studied does not confer prognostic value, making it impossible to use as a prognostic tool in peripheral blood, we are leaving the doors open to continue with this line of research, possibly increasing the number of patients as well as prolonging the follow-up time

    Palliative prognostic index and Charlson comorbidity index as predictors of mortality in acute lymphoblastic leukaemia patients who are candidates for palliative care

    No full text
    Objective: To establish whether the palliative prognostic index (PPI), the Charlson comorbidity index (CCI) or other factors are predictors of survival for patients with ALL undergoing palliative care. Materials and methods: Retrospective cohort study of patients diagnosed with ALL undergoing palliative care. We analysed variables at the time of diagnosis (age, WBC count, and risk type), chemotherapy regimens received, PPI, CCI and transfusion requirements at time palliative care was started. Results: We studied 32 patients with a mean age of 37 (18鈥75) years. Fourteen cases had a PPI聽=聽0 (43.8%). 62.5% (n聽=聽20) with a CCI聽>聽3 had high odds of dying within 10 years. The median survival was 200 days, unaffected by any of the factors analysed. Discussion: Neither PPI, CCI, nor the other studied factors effectively predicted survival. Scales will have to be adapted or new predictive scales devised specifically for patients with ALL. Resumen: Objetivo: Establecer si el 铆ndice pron贸stico paliativo (IPP), el 铆ndice de comorbilidad de Charlson (ICC) u otros factores son predictores de sobrevida en pacientes con LLA sometidos a terapia paliativa. Material y m茅todos: Cohorte retrospectiva de pacientes con diagn贸stico de LLA sometidos a terapia paliativa. Se analizaron variables al momento del diagn贸stico (edad, cifra de leucocitos, tipo de riesgo), esquemas recibidos, IPP e ICC al momento de iniciar tratamiento paliativo, as铆 como los requerimientos transfusionales. Resultados: Se estudiaron 32 pacientes con edad promedio de 37 (18鈥75) a帽os. Catorce casos obtuvieron un IPP de 0 (43.8%). El 62.5% (n聽=聽20) con ICC >3 ten铆a altas probabilidades de morir en menos de 10 a帽os. La media de supervivencia fue de 200 d铆as, sin afectarse significativamente por ninguno de los factores analizados. Discusi贸n: IPP, ICC, ni otros factores predijeron efectivamente la sobrevida. Ser谩 necesario adecuar estas escalas o idear nuevas espec铆ficamente para LLA. Keywords: Palliative care, Prognosis, Precursor cell lymphoblastic leukaemia-lymphoma, Survival, Palabras clave: Cuidados paliativos, Pron贸stico, Leucemia-linfoma linfobl谩stico de c茅lulas precursoras, Supervivenci

    Expression of genes MAGE-A3 MAGE-C1, NY-ESO-1 and SSX1 in patients with multiple myeloma at the General Hospital of Mexico

    No full text
    Multiple myeloma is the most common form of plasma cell cancer. It is a disease of elderly people, with a mean age at diagnosis of 65鈥70, and represents 10鈥15% of all blood cancers. It is a heterogeneous disease associated with intrinsic factors and disease characteristics such as genetics, which dictate the clinical course of the disease. Multiple myeloma involves several abnormalities in the IgH variable region. The first oncogenic events in this cancer occur in the germinal centre, apparently during isotype switching and somatic hypermutation of B cells. While these primary mutations have been found in myeloma cells, these events alone are not enough to cause pathogenesis. However, few genes have been identified in this type of disease. The expression of cancer/testis antigens (CTAs) is limited to testis tissue and various types of cancer, in which they are considered as a tumour marker as they are associated with the prognosis and monitoring of the disease, and are involved with overall survival and event-free disease. In view of the above, the objective of this study was to analyse the expression of CTAs (MAGE-A3 and -C1, NY-ESO and SSX1) by RT-PCR in patients diagnosed with de novo multiple myeloma admitted to the Haematology Department of Hospital General de M茅xico. Our results proved that there is presence of these genes and that they may be involved in resistance, progression and survival. Resumen: El mieloma m煤ltiple es la forma m谩s com煤n de las neoplasias malignas de c茅lulas plasm谩ticas. Es una enfermedad de los adultos mayores, la media al diagn贸stico es de 65 a 70 a帽os y representa del 10 al 15% de todas las neoplasias hematol贸gicas. Es una enfermedad heterog茅nea donde existe una asociaci贸n con factores y caracter铆sticas intr铆nsecas de la enfermedad, tales como las gen茅ticas, las cuales dictan el curso cl铆nico del padecimiento. El mieloma m煤ltiple involucra diversas anormalidades en la regi贸n variable de la IgH. Los primeros eventos oncog茅nicos en esta neoplasia ocurren en el centro germinal, al parecer durante el proceso de cambio de clase de isotipo y de hipermutaci贸n som谩tica de las c茅lulas B. Si bien estas mutaciones primarias han sido encontradas en c茅lulas mielomatosas, estos eventos por s铆 solos no son suficientes para provocar la patog茅nesis. Sin embargo, son escasos los genes identificados en este tipo de padecimiento. La expresi贸n de los ant铆genos testiculares de c谩ncer (ATC) se limita a tejido testicular y a varios tipos de c谩nceres, en donde ha sido considerada como marcador tumoral, pues est谩n implicados en el pron贸stico y seguimiento de la enfermedad, impactando en la supervivencia global y en la enfermedad libre de eventos. Por lo tanto, el objetivo de este trabajo fue analizar la expresi贸n de los ATC (MAGEA3, C1, NY-ESO y SSX1) en pacientes diagnosticados con mieloma m煤ltiple de novo que ingresaron al Servicio de Hematolog铆a del Hospital General de M茅xico por medio de RT-PCR. Nuestros resultados comprobaron que existe presencia de dichos genes, por lo que podr铆an estar participando en la resistencia, progresi贸n y supervivencia. Keywords: Cancer/testis antigens, Multiple myeloma, RT-PCR, Palabras clave: Ant铆genos testiculares de c谩ncer, Mieloma m煤ltiple, RT-PC

    Detection and analysis of tumour biomarkers to strengthen the diagnosis of acute and chronic leukaemias

    Get PDF
    AbstractMolecular markers in leukaemia are essential to diagnose, establish prognosis factors and determine the correct treatment of patients; therefore, it is imperative to include molecular biology studies, so that, combined with cytomorphology and immunophenotyping studies, they constitute the differential diagnosis of these neoplasias. It is extremely important to implement a panel of molecular markers that allows us to detect oncogenes derived from chromosomal translocations, genes derived from epigenetic alterations and drug-resistant genes.A panel of molecular markers that included 11 genes derived from chromosomal translocations BCR-ABL major and minor breakpoints, E2A-PBX1, MLL-AF4, TEL-AML1, PML-RAR伪, AML1-ETO was standardised; cancer testis antigens (CTA) derived from NY-ESO1 and MAGE-A3 epigenetic alterations and multi-drug-resistant genes ABCB1 and ABCG2. 30 patients diagnosed with leukaemia from Mexico's General Hospital (Hospital General de Mexico) were included. They suffered from acute lymphoblastic leukaemia (ALL) and acute myeloblastic leukaemia (AML); bone marrow mononuclear cells were used, from which RNA was extracted for the synthesis of cDNA and RT-PCR for each of the markers. In acute lymphoblastic leukaemia (ALL), BCR-ABL biomarkers expressed under 30% (3/10), E2A-PBX1 10% (1/10), ABC-B1 80% (8/10), and ABC-G2 60% (6/10). Patients with acute myeloblastic leukaemia (AML) expressed 30% PML-RAR伪 (3/10), 40% ABC-B1 (4/10), and 10% ABC-G2 (1/10). Lastly, in patients with chronic myeloid leukaemia (CML), BCR-ABL was over 100% (10/10), ABC-B1 20% (2/10), and ABC-G2 50% (5/10). The presence of transcripts from chimeric genes minor BCR-ABL and E2A-PBX1 in ALL; PML-RAR伪 in AML; and major BCR-ABL in CML, confirms the importance that the panel of molecular markers has in strengthening the diagnosis and prognosis of these conditions

    Retrospective analysis of therapeutic response obtained with enteral and parenteral iron in adults with iron deficiency anaemia

    Get PDF
    AbstractBackgroundFew studies compare the therapeutic efficacy of different iron deficiency anaemia treatments.AimEvaluate the therapeutic response of the most common iron preparations.Material and methodsRetrospective, observational-analytical study based on medical records from the Haematology Department, conducted from March to October 2014, including 121 adults with ferropenic anaemia and 3-month follow-up. Patients with comorbidities or pregnancy were excluded.Results85.8% were women (n=103) and 14% men (n=17), with a mean age of 42 (16鈥83) years. Seventy patients (58.3%) started with oral administration; the rest received intravenous iron. Efficacy was similar among all the iron preparations, with no significant differences (p>0.05). Iron sucrose was most effective in rapidly replenishing body iron stores.ConclusionsDespite comparable efficacy among treatments, ferrous fumarate had the lowest treatment failure and was the therapy of choice
    corecore